Three lenses for judging any longevity offer, and the one filter that separates a health business from a scheme built on what you do not know.
When my earlier piece on the "dirty secret of longevity" started circulating, a lot of readers assumed I had written a takedown of drips and gadgets. I had not. What I was actually pointing at is quieter and more structural. In most of healthcare, nobody in the room is paid to ask the only question that decides whether you got value: do you actually need this, and will it leave you healthier on net? Modern medicine is not short on data or devices. It is short on incentives to tell you the truth. Ethics is optional in the business model, and that is the missing ingredient.
This is an educational and strategic perspective, not personal medical advice.
Why this market rewards selling the wrong thing
Health and wellness look wonderful from a distance. Spend keeps rising, the wellness economy runs into the trillions, and the "longevity" corner grows fast because the demand is emotionally locked in. Everyone ages. Everyone fears decline. In any other sector you would ask where the growth is mispriced. In this one the answer is uncomfortable.
We have strong, repeatable evidence that a handful of boring things move hard outcomes: controlling blood pressure, building cardiorespiratory fitness, staying physically active, sleeping properly, and running screening at the intervals the guidelines actually support. We have much weaker evidence that vitamin drips, stacked peptides, and open-ended "optimization" protocols do anything for a healthy person beyond a pleasant afternoon and a placebo bump, while still carrying cost and risk. Capital flows toward the second list, not the first.
That is not stupidity. It is structure. Health is what economists call a credence good: you usually cannot verify whether what you bought did anything. The seller looks like they know more than you. And most of the real payoff from prevention lands years later, on the public system and your family, not on this quarter's invoice. In that setting, selling something plausible is cheap and selling only what works is expensive.
Three lenses for judging any longevity offer
You do not need a medical degree to protect yourself here. You need a few honest questions and the nerve to ask them out loud.
Evidence lens: Ask where each recommendation sits. Strong human outcome data? Early but promising human data? Animal or mechanism only? Or frank speculation dressed up as frontier science? A serious provider can tell you which tier a given intervention lives in without flinching.
Sequence lens: Ask what comes first. If a provider offers you full body scans, injectables, or exotic panels before anyone has looked hard at your sleep, blood pressure, lipids, movement, and mental load, the sequence is backwards. The boring work belongs at the front, not as an afterthought once the exciting invoices are booked.
Incentive lens: Ask where the money sits. If the margin lives in drips, devices, and high ticket packages, and the staff are rewarded for upgrades, then every time someone tells you "you do not need that," they are cutting their own contribution margin. In that model, honesty is a cost. You want to know that before you sign anything.
Red flag test: If the consultation feels half clinical and half sales floor, and the story you are told scales neatly with the price you are about to pay, treat that as a warning, not reassurance. People paying premium annual fees rarely want to hear "you mostly need to sleep, walk, lift, and manage one number." So the industry sells a complicated narrative that feels proportional to the spend. Complexity is often the packaging, not the treatment.
The one filter I use on any provider
Boundary: Here is the single question I now apply to any longevity business, including my own. Would this company still be viable if every clinician told every client the whole truth about what they actually need, including "you do not need most of this"?
If the honest answer is no, you are not looking at a healthcare company. You are looking at an extraction scheme built on top of the gap between what the seller knows and what you know. That can be profitable. Plenty of things are. But it is not care, and you should price it accordingly.
Ethical debt: the liability nobody puts on the model
Operators track leverage, regulatory risk, and reputational risk. I think this sector needs one more line item, and it is worth understanding as a buyer too. Call it ethical debt: the growing gap between the product set you know would be defensible and net positive, and the one you actually sell because it is profitable and the market currently tolerates it.
A business runs up ethical debt when it adds a service mainly because it photographs well, keeps a high billing clinician whose numbers depend on overselling, pushes scans outside the evidence, or treats prevention as marketing rather than the actual engine. Like technical debt, it compounds quietly and gets expensive to unwind. Unlike technical debt, it plays out in real bodies. Tradeoff: a provider that refuses this debt will feel less dazzling on day one and more trustworthy at month six. That is the trade you want to be on the right side of.
Health is one of the few products you can actually feel
Most products can hide behind brand and perception. Health cannot, at least not forever. If your sleep improves, you notice. If your fitness climbs and your blood pressure settles, you feel it in your body. That makes this an unusual market: the benefit is embodied, not imagined. A provider that genuinely delivers more energy, fewer symptoms, and lower risk should earn loyalty the way a good tool does, because leaving would cost you something real. A provider selling novelty has to keep you moving between the next protocol and the next device. If a place needs constant new shiny things to hold your attention, ask what that says about the last ones.
A short FAQ
Does ethics-first mean anti-technology? No. It means frontier tools are gated, not banned. They come after the foundations are mapped and managed, and only when they plausibly add something beyond doing the basics better.
Is advanced imaging or a full panel always a bad sign? Not at all. The question is sequence and indication. The right test for the right person at the right stage is good medicine. The same test sold to everyone on day one is a revenue tactic.
How do I use these lenses without being an expert? You do not judge the science. You judge the structure: can they name the evidence tier, will they do the boring work first, and where does their money come from. Honest providers answer all three easily.
How Atlas Cove approaches this
Atlas Cove exists because I did not want to critique this market while quietly reproducing it in nicer stone. So we wrote ethics in as a design constraint, not a slogan. Everything runs through the same filters above. Foundations first and non-negotiable: movement and strength, practical cardio, sleep, metabolic basics, and mental load. Then an evidence-aligned medical and prevention layer, read by prevention-oriented physicians with explicit evidence tiers. Only then, and tightly gated, do we consider frontier tools, each tagged by evidence level and matched to a specific profile. The blunt house rule is that nobody reaches the shiny stuff until we have done the work on the boring stuff. That reshapes our economics on purpose: we cannot hit our numbers by selling drips to tired executives, so we make honest prevention and interpretation the product itself, and let retention follow how you actually feel six months in.
This is an educational and strategic perspective, not personal medical advice.
Lisa Wuerden · Co-Founder
Co-founder, brand and product